Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiomyopathy
Pharma
Cytokinetics scores its first FDA nod with Myqorzo approval
The FDA has signed off on Cytokinetics’ potential blockbuster hypertrophic cardiomyopathy (oHCM) treatment Myqorzo.
Kevin Dunleavy
Dec 22, 2025 12:05pm
Is Pfizer's recent ATTR sales decline in the US a warning sign?
Dec 2, 2025 8:20am
Fierce Biotech
Cytokinetics doesn't want Big Pharma help to overtake Camzyos
Nov 18, 2025 1:30pm
Cytokinetics joins Bristol Myers in funding heart registry
Nov 17, 2025 12:45pm
Pfizer to discontinue low-dose ATTR drug Vyndaqel in US in 2025
Aug 29, 2025 10:40am
Alnylam's Amvuttra off to promising start in ATTR-CM
May 1, 2025 11:46am
